Scarica l'app Stockscreener
42.16
7.03%
2.77
Dopo l'orario di chiusura:
41.32
-0.84
-1.99%
Precedente Chiudi:
$39.39
Aprire:
$39.41
Volume 24 ore:
1.85M
Relative Volume:
1.22
Capitalizzazione di mercato:
$2.80B
Reddito:
-
Utile/perdita netta:
$-119.67M
Rapporto P/E:
-15.44
EPS:
-2.73
Flusso di cassa netto:
$-97.30M
1 W Prestazione:
+10.77%
1M Prestazione:
+9.34%
6M Prestazione:
+245.86%
1 anno Prestazione:
+214.16%
Intervallo 1D:
$39.28
$42.71
Intervallo di 1 settimana:
$35.31
$42.71
Portata 52W:
$8.241
$42.71
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER ROAD, RADNOR
Confronta MLYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
42.16 | 3.06B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
A Look at Mineralys Therapeutics's Valuation as Phase 2 EXPLORE-OSA Trial Reaches Enrollment Milestone - simplywall.st
What MACD signals say about Mineralys Therapeutics Inc.2025 Earnings Surprises & AI Powered Buy and Sell Recommendations - newser.com
Has Mineralys Therapeutics Inc. formed a bullish divergenceQuarterly Market Summary & Reliable Breakout Forecasts - newser.com
Understanding Mineralys Therapeutics Inc.’s price movementShare Buyback & Real-Time Buy Signal Notifications - newser.com
Mineralys Therapeutics (MLYS) Is Up 10.8% After Completing Phase 2 OSA Trial Enrollment – What's Changed - simplywall.st
Mineralys Therapeutics stock hits all-time high at 41.11 USD - Investing.com
Mineralys Therapeutics (NASDAQ:MLYS) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Published on: 2025-10-10 04:36:23 - newser.com
Is Mineralys Therapeutics Inc. stock reversal real or fakeJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
Forecasting Mineralys Therapeutics Inc. price range with options dataTrade Signal Summary & Consistent Profit Trade Alerts - newser.com
EXPLORE-OSA Drug Candidate Trial Fully Enrolled - Sleep Review
Real time breakdown of Mineralys Therapeutics Inc. stock performanceJuly 2025 Levels & Reliable Momentum Entry Alerts - newser.com
Can Mineralys Therapeutics Inc. recover in the next quarterEarnings Risk Report & Fast Momentum Entry Tips - newser.com
Mineralys Therapeutics Inc. stock chart pattern explainedJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
Published on: 2025-10-09 03:22:25 - newser.com
Tick level data insight on Mineralys Therapeutics Inc. volatility2025 Biggest Moves & Real-Time Sentiment Analysis - newser.com
Will Mineralys Therapeutics Inc. see short term momentumJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Mineralys Therapeutics Announces Q1 2025 Financial Results and Achievements - MSN
What drives Mineralys Therapeutics Inc stock priceEarnings Season Recap & Low Risk Trading Ideas - earlytimes.in
Can swing trading help recover from Mineralys Therapeutics Inc. lossesJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Applying Wyckoff theory to Mineralys Therapeutics Inc. stockWeekly Trend Recap & Expert Curated Trade Setup Alerts - newser.com
What’s next for Mineralys Therapeutics Inc. stock priceJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Mineralys Therapeutics Inc.’s volatility index tracking explained2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Mineralys Completes Enrollment in Phase 2 Sleep Apnea and Hypertension Trial - MyChesCo
Is Mineralys Therapeutics Inc. stock poised for growthTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Tools to assess Mineralys Therapeutics Inc.’s risk profileJuly 2025 Gainers & Free Safe Entry Trade Signal Reports - newser.com
Statistical indicators supporting Mineralys Therapeutics Inc.’s strengthJuly 2025 Action & Community Consensus Stock Picks - newser.com
What does recent volatility data suggest for Mineralys Therapeutics Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - newser.com
Top chart patterns to watch in Mineralys Therapeutics Inc.2025 Market WrapUp & Expert Approved Trade Ideas - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 5.2%Here's Why - MarketBeat
Could Mineralys Therapeutics (MLYS) Trial Progress Hint at a Broader Hypertension Strategy? - simplywall.st
Mineralys Therapeutics Announces Public Offering of Shares - MSN
uniQure, Dianthus Therapeutics, and Mineralys Therapeutics Lead September 2025 Biotech Funding Rounds - geneonline.com
The biggest biotech funding rounds in September 2025 - Labiotech.eu
Why Mineralys Therapeutics (MLYS) Is Up 5.1% After Completing Enrollment in EXPLORE-OSA Hypertension Trial - Yahoo Finance
A Fresh Look at Mineralys Therapeutics (MLYS) Valuation Following New Clinical Milestones for Lorundrostat - simplywall.st
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts - MSN
Mineralys: Lorundrostat Continues To Deliver Hypertension Market Expansions (MLYS) - Seeking Alpha
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension - Sahm
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):